Takeda and Lundbeck lay out Phase III plans under depression alliance
This article was originally published in Scrip
Takeda and Lundbeck have unveiled details of new pivotal Phase III programmes for two novel molecules for major depressive disorder (MDD) being co-developed under their 2007 alliance for mood and anxiety disorder drugs.
You may also be interested in...
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.